Written By: Cameron Scott — Singularity Hub
There are certain words that you would never want to hear coming from a healthcare provider. “Salvage chemotherapy” and “Hail Mary transplant” would rank high on that list for most of us.
And yet it was patients who weren’t even eligible for these treatments or for whom they’d already failed who participated in a recent clinical trial for a cell therapy treatment for adult B-cell acute lymphoblastic leukemia, or B-ALL, led by Michel Sadelain at Memorial Sloan Kettering Cancer Center.
Nearly 90 percent achieved complete remission of the disease, the researchers reported today in Science Translational Medicine.
Comments are closed.